Monday, August 31, 2015

Awards sponsored by the American Journal of Physiology-Lung Cellular and Molecular Physiology

The editors of the AJP-Lung and the APS are sponsoring a number of awards to recognize outstanding papers published in this journal.  They include one award for the Best Research Paper, three for the Hermann Rahn Award and two for the Usha Awards.  Please see the information in the APS webpage
We are looking forward to nominations and self-nominations. 
Sadis Matalon

Wednesday, August 5, 2015

APSselect features two AJP-Lung papers in August

APSselect is a collection of the very best original research papers published by the American Physiological Society.  Congratulations on our newest two APSselect winners for August.

Valeriy Poroyko and his colleagues for

Alterations of lung microbiota in a mouse model of LPS-induced lung injury
vol. 309: L76-L83, 2015. DOI: 10.1152/ajplung.00061.2014

Kelly S. Schweitzer et al, for their work:

Endothelial disruptive proinflammatory effects of nicotine and ecigarette vapor exposures.
vol. 309: L175-L187, 2015. DOI: 10.1152/ajplung.00411.2014

To view all the "best" papers that the American Physiology Society published in August  please visit

Tuesday, August 4, 2015

Call for papers: Electronic cigarettes: not all good news?

Electronic cigarettes (e-cigs) are battery-operated devices which heat a liquid that contains nicotine, flavors, and additives and, in some cases, varying amounts of other unknown compounds, which are not regulated by the FDA. Aggressive advertising by e-cigs manufacturers implies these devices are less harmful and represent a “safe” alternative to conventional cigarette smoking. E-cigs reportedly contain less carcinogens than traditional cigarettes, with a predominance of nicotine in e-cig vapors that has led to them being variably called “nicotine delivery devices”. Thus, the assumption is that e-cigs cause less lung injury in the healthy user, and may help conventional cigarette users to quit smoking. Furthermore, e-cigs are viewed as being potentially safe for asthmatic smokers. Based on these purported safety profiles, e-cig use is increasing at an alarming rate.

In spite of the increasing use of e-cigs, data on their short- or long-term detrimental effects and toxicity are missing. In addition to the fact that the local heating and “vape” delivery by e-cigs has the potential to deliver substantially higher levels of nicotine to the upper and lower airways, e-cigs also contain formaldehyde, hemiacetals that can form formaldehyde, acrolein, and particulate matter, all of which can be potentially harmful. Furthermore, local delivery of e-cig products to the oropharynx and upper airways has the potential to substantially influence the oral and bronchial epithelium and salivary glands, thus influencing mucus membrane properties, barrier function, and immune responses and responsivity.  Indeed, salivary gland dysfunction can lead to periodontal disease, gingivitis, bacterial colonization, and loss of enamel mineralization.  These conditions are often encountered in conventional smokers and may be present in e-cig users as well. Similarly, higher nicotine or other product levels may adversely influence upper airway irritability, reflex bronchoconstriction and other key aspects of airway function. Finally, the influence of e-cig products on the alveolar epithelium and the pulmonary endothelium are still under exploration. In a recently article published in AJP-Lung and highlighted in a variety of electronic media,  Dr. Petrache and her collaborators demonstrated that nicotine and other components present in e-cigs damaged endothelial cells and increase endothelial permeability in addition to damaging airway and alveolar epithelia: Clearly additional research is needed on this very interesting topic

The American Journal of Physiology-Lung Cellular and Molecular Physiology is issuing a call for papers addressing key questions in the mechanisms and potentially toxic effects of e-cigs as it applies to the cardiopulmonary system and other organs that may be targeted.  All manuscripts will be reviewed promptly, thoroughly, and fairly by members of the Editorial Board and guest reviewers who are recognized experts in this field. Accepted manuscripts will be published on line within two weeks after acceptance under a distinct heading and will receive special attention and handling. In addition, the Editor will solicit an annual perspective on this area to review seminal findings. Only those papers not requiring extensive revision will be published under this call for papers. 

This call for papers is effective between August 1st, 2015 and October 1st, 2017.